Insider Trading Pulse — July 24, 2026

CEO Carmel Sharon bought 82,650 shares at $1.29 for a total of ~$106K, increasing his stake to 3.65M shares. This is a high-conviction open-market purchase by the top executive, signaling strong belief in the company's undervaluation and future prospects.

Chief Banking Officer Robert A. McCabe Jr. bought 10,013 shares at $99.90 for ~$1M. This is a substantial open-market purchase by a key revenue-generating executive, a strong vote of confidence in the bank's loan growth and financial health.

Director Choo Chee Kong bought 200,000 ordinary shares at $1.50 for a total of ~$300K. This aggressive accumulation by a director in a small-cap biotech signals strong insider conviction in upcoming catalysts or a perceived deep value.

COO Ye Gang sold 9,952 shares at $105.59 for ~$1.05M and CCO Wang Yanjun sold 568 shares at $104.75 for ~$59.5K. Both trades were executed under Rule 10b5-1 plans, reducing the bearish signal but still representing significant cash-outs by top executives near recent highs.

CEO Jordan Kovler sold 35,721 shares at $2.45 (~$87.5K) and CFO Christian Mulvihill sold 14,738 shares at $2.45 (~$36.1K). Simultaneous selling by the two highest-ranking officers is a significant red flag for the crypto mining company, suggesting internal concerns about valuation or operations.

EVP & CLO James CI Lee sold 542 shares at $905.01 for ~$491K. This is a large, six-figure sale by a top legal officer, which can be a bearish signal, especially given the stock's high price and the executive's relatively small remaining stake of 1,018 shares.

SVP & Corp. Controller Paul E. Munson exercised 1,525 options at $126.18 and immediately sold the shares at $369.91 for a ~$372K profit. This is a classic cash-out of a large options position, which can be interpreted as the insider taking profits off the table.

Director Lynn Vojvodich Radakovich exercised 2,022 options at $31.14 and sold the shares at $413.77 for ~$837K. This is a massive profit-taking event by a director, executed under a 10b5-1 plan, but the sheer size of the gain realized is notable.

Chief Administration Officer Uang Du-Tsuen sold 3,000 ordinary shares at $665 for ~$2M. This is a very large, high-value sale by a senior executive, signaling a potential top in the stock or a desire to diversify a concentrated position.

Wolverine Asset Management LLC, a 10% owner, sold 184,038 shares at $12.06 for ~$2.2M. This is a major exit by a significant institutional holder in a SPAC, a very bearish signal for the de-SPAC process.

Both the CEO and CFO sold shares on the same day at the same price ($2.45). This coordinated selling by the two most senior officers is a high-risk signal, potentially indicating severe operational or liquidity issues.

A 10% owner, Wolverine Asset Management, sold nearly $2.2M of stock. In a SPAC, such a large sale by a major backer before a business combination is a strong vote of no confidence and increases the risk of deal failure or poor post-merger performance.

CEO David Tobias sold 149,538 shares at $0.01 for a paltry ~$1.15K. While the dollar value is low, the CEO is selling a large number of shares at a penny stock price, which is a classic sign of a distressed or potentially fraudulent company.

While under 10b5-1 plans, the COO and CCO sold over $1.1M in stock. The use of 10b5-1 plans does not eliminate the concern, as executives can set up plans when they know future performance may soften. This warrants monitoring of upcoming earnings.

Chief Strategy Officer Michael James Hogan sold his remaining 707 shares, leaving him with only 0.496 shares. An insider selling down to nearly zero is a strong negative signal, suggesting a complete lack of confidence in the stock's future.

SVP & Corp. Controller Munson sold 100% of his exercised shares for a ~$372K profit. This is a large, unambiguous cash-out by a senior financial officer, which can be a leading indicator of a peak in the stock price.

Energy Manager Guillermo Del Castillo Cacho sold a total of 15,300 shares across multiple transactions at ~$3.40, reducing his stake significantly. Selling by a non-C-suite officer can sometimes be a leading indicator of operational issues.

An executive (Azaria Eynav) sold 6,301 shares at $1.42 for only ~$8.97K. Selling at such a low stock price is a bearish signal, as it suggests the insider sees little near-term upside.

The CEO's $106K open-market purchase at $1.29 is a powerful signal. For a small-cap tech company, such a direct investment by the top executive is a strong buy signal, especially if the company has upcoming product launches or earnings.

The Chief Banking Officer's $1M open-market purchase at $99.90 is a massive vote of confidence. This suggests the bank's loan book is strong and management sees the stock as undervalued relative to its growth prospects.

A director buying $300K worth of shares in a small-cap biotech is a strong catalyst signal. This often precedes positive clinical trial data, partnership announcements, or a strategic review.

CEO Elizabeth Anne McDonald was awarded 90,168 RSUs and COO Blake McKenna was awarded 46,639 RSUs. These large performance-based grants align management with shareholders and suggest the board is confident in future operational and stock price performance.

A 10% owner bought 15,255 units at $10.79 for ~$165K. This is a strong signal from a sophisticated institutional investor who is adding to a position, indicating a belief that the fund's assets are undervalued.

Director Moritz A. Sell bought 2,000 shares at $5.86 for ~$11.7K. This is a small but positive signal from a director, suggesting the fund's net asset value or income stream is attractive at current levels.

Horizon Kinetics Asset Management bought 1 share at $429.51. While a tiny purchase, it is a symbolic signal from a major, value-oriented institutional holder that they are not selling and are willing to add even at the margin.

Chairman & CEO John Holmes was awarded a total of 211,705 shares and CFO Dylan Wolin was awarded 9,655 shares. These are massive equity grants that strongly align management with long-term shareholder value creation.

The technology sector shows a clear split in insider sentiment. On one side, Sea Ltd (SE) executives are cashing out over $1.1M in stock. On the other, Beamr Imaging's CEO is buying $106K. This suggests a 'stock-picker's market' where company-specific fundamentals, not sector tailwinds, are driving insider conviction.

In the financial sector, insider activity is mixed. A Pinnacle Financial Partners executive made a $1M open-market buy, signaling strong confidence in regional banking. Conversely, a PNC executive sold $303K, and a Travelers executive cashed out a large options position. This points to a bifurcated outlook where well-managed, growth-oriented banks are favored over larger, more mature institutions.

The energy sector, represented by SM Energy Co, shows a pattern of large, long-term incentive grants to top executives (CEO, COO). This is a neutral-to-bullish signal, indicating the board is tying management compensation to future performance and stock price appreciation, rather than insiders making short-term market calls.

The crypto mining sector is flashing a clear warning signal. At Greenidge Generation (GREE), both the CEO and CFO sold shares simultaneously. This coordinated insider selling, combined with the stock's low price, suggests significant internal distress and a lack of confidence in the business model's near-term viability.

The small-cap biotech sector shows a strong insider buy signal. Director Choo Chee Kong's $300K purchase of CytoMed Therapeutics (GDTC) shares is a high-conviction bet. This pattern often precedes material corporate events and suggests the risk/reward is heavily skewed to the upside for the informed insider.

The SPAC sector is showing a pattern of insider exit. The $2.2M sale by a 10% owner in Four Leaf Acquisition Corp (FORL) is a strong negative signal. This suggests that sophisticated investors are losing patience with the de-SPAC process and are choosing to exit rather than wait for a potential merger. This theme could spread to other SPACs.

Watch for Q2 2026 earnings. The C-Suite stock sales under 10b5-1 plans could be a precursor to softer guidance or a slowdown in growth. The next earnings call will be critical to assess the company's outlook.

Monitor for any operational updates or financing announcements. The simultaneous CEO and CFO stock sales are a major red flag. Any news of debt restructuring, asset sales, or a going concern warning would be a negative catalyst.

The Chief Strategy Officer selling down to nearly zero shares is a strong negative signal. Watch for any insider selling by other C-suite executives, which would confirm a broader loss of confidence. The next earnings report will be key.

The $1M insider buy by the Chief Banking Officer is a strong positive signal. Monitor the stock price for any pullback, which would be a better entry point. The next quarterly results will validate or invalidate this insider's confidence.

The director's $300K purchase is a potential catalyst signal. Watch for any press releases regarding clinical trial results, partnership agreements, or regulatory milestones in the coming weeks.

The CEO's $106K purchase is a strong buy signal for a small-cap. Monitor for any new customer announcements, product updates, or earnings beats that could validate the insider's conviction and drive the stock price higher.

Watch for any announcements regarding a target business combination. The large insider sale by a 10% owner significantly increases the risk that a deal will be unfavorable for minority shareholders or will fail entirely.

The director's massive options exercise and sale is a notable event. Watch for any other insider selling activity. The stock's performance leading into the next earnings report will be a key test of market sentiment.